Certifications
Accreditations

In addition to the recognized certifications from Swissmedic and the Federal Office of Public Health (FOPH), our laboratory also meets international standards and holds a variety of other accreditations. These reflect our continuous commitment to meeting globally recognized quality requirements and ensuring that our processes and services are carried out at the highest level. The following international accreditations highlight our expertise and our ability to maintain the highest quality standards in a global context:

We would like to emphasize that our AABB certification, together with FACT-NetCord, represents the two globally recognized excellence standards for umbilical cord blood banks. These two standards are internationally leading and ensure the highest quality in the processing and storage of umbilical cord blood. Additionally, the AABB certification is also recognized as a key excellence standard for tissues (umbilical cord and placenta), highlighting its significance and influence on the entire industry.

Our laboratory is also a member of leading international professional organizations. These memberships allow us to continuously exchange knowledge on current developments and benefit from established standards. They underscore our commitment to quality and our close connection to relevant professional networks.

FamiCord Suisse operates according to extremely strict and comprehensive quality protocols that are certified and accredited. These protocols reflect the highest international standards and ensure that all processes involved in the processing and preservation of stem cells are carried out with the utmost precision and care. Through continuous review and optimization of our workflows, we ensure that our stem cells are processed and stored in an absolutely safe and controlled environment, guaranteeing the highest quality and safety for our customers.

In addition, the FamiCord Group is the only stem cell bank in Europe authorized to manufacture ATMPs (Advanced Therapy Medicinal Products). These innovative therapies use stem cells as medicines, offering new approaches in medicine. The FamiCord Group has already demonstrated the capability to experimentally provide such ATMPs, marking a significant step toward future treatment options. This authorized status underscores our leadership in stem cell technology and our ongoing efforts to develop pioneering therapeutic solutions.